Printer Friendly

Cardiome obtains additional oxypurinol patent.

Cardiome Pharma Corporation (Vancouver, Canada) announced that the United States Patent and Trademark Office has issued a new patent providing additional protection to Cardiome's program focused on treatment of congestive heart failure with oxypurinol.

United States Patent 6,569,862, was the second issued to the Johns Hopkins University (Baltimore, MD) in this field. The key claims in the new patent cover use of the entire family of drugs known as xanthine oxidase inhibitors applied to contractile disorders of the heart, including congestive heart failure. An earlier patent issued to Johns Hopkins contained provisions relating to a specific mechanism of action and to specific forms of heart disease. Both patents and related intellectual property are licensed exclusively to Cardiome. The invention underlying both patents, originally described by Dr. Eduardo Marban of Johns Hopkins, involves the novel observation that these agents appear to increase cardiac work output without increasing cardiac oxygen consumption.

"Cardiome's ongoing clinical studies on the use of oxypurinol may open a major new option in the treatment of patients," said Dr. Alan Ezrin, Cardiome's Chief Scientific Officer. "This broader patent coverage can only increase the commercial value of our potential breakthrough approach to congestive heart failure therapy."

Congestive heart failure ("CHF") is a disease characterised by an inability of the heart to pump blood at a rate sufficient to support the needs of the body.

Cardiome is currently conducting four clinical studies utilizing oxypurinol to treat patients with congestive heart failure. The key clinical study, OPT-CHF, is a Phase II/III oral study enrolling 400 patients to measure clinical endpoints such as mortality and rehospitalization. Three smaller proof-of-concept studies will observe surrogate endpoints such as cardiac output and exercise tolerance. The first of these studies will be completed soon, with results to be presented at the Heart Failure Society of America meeting in September.

Congestive heart failure is a common disease whose incidence and severity increase with age, and is a significant cause of death in the developed world. Congestive heart failure is also an important risk factor for serious disorders of the cardiac rhythm, and is associated with a 6 to 9 fold increase in the risk of sudden cardiac death. The condition also significantly reduces the quality of life in those who suffer from the disease. Approximately 4.7 million persons in the United States suffer from congestive heart failure, while the developed world total is estimated at approximately 10 million.

Although some of the existing drugs used to treat congestive heart failure can provide a short- term increase in the heart's ability to pump blood, they do so at the cost of exacerbating the underlying disease. Such drugs increase contractile energy at the expense of increasing the heart's utilization of oxygen and energy.

Xanthine oxidase inhibitors may improve myocardial work efficiency by sensitising cardiac muscle cells to calcium ions, which are a key determinant of cardiac muscle function. These calcium-sensitized cardiac cells contract more efficiently without the same increase in oxygen demand.

Cardiome is a product-focused cardiovascular drug development company. Cardiome has three late stage clinical drug programs focused on atrial arrhythmias, congestive heart failure, and hyperuricemia (gout).

Cardiome's lead antiarrhythmic product, RSD1235, is an acute-use, intravenous administration treatment for atrial fibrillation. RSD1235 selectively blocks ion channels in the heart that are known to be active during episodes of atrial fibrillation. This unique mechanism of action of antiarrhythmic product, combined with supportive preclinical and clinical data, suggests that it may be able to effectively treat atrial arrhythmia with a high margin of safety. In a phase II study completed in the fall of 2002 with new onset atrial fibrillation patients (n equals 56), RSD1235 terminated atrial fibrillation in 61% of patients versus 5% placebo within 30 minutes of the end of infusion (p equals 0.0003). Currently available drugs to acutely treat atrial fibrillation lack sufficient efficacy and have serious safety risks. These safety issues include risk of drug induced proarrhythmia and other cardiac liabilities. To date, no significant drug-related adverse events have been reported in patients exposed to RSD1235.

Cardiome's lead product in the congestive heart failure area is oxypurinol, a novel therapy in treating the disease. Cardiome also plans to develop oxypurinol as a treatment of gout for patients who are intolerant to allopurinol, the first-line therapy for gout.

Cardiome Pharma Corp.

COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1CANA
Date:Jul 1, 2003
Previous Article:CuraGen develops of predictive drug development assay.
Next Article:ActivBiotics announces patent issuances covering bacterial infection treatments.

Related Articles
ILEX Oncology acquires Convergence.
Hollis-Eden expands its intellectual property position and acquires minority interest in Aeson Therapeutics.
Protein Design announces agreement with MedImmune.
Forest and Merz File Additional Lawsuit Against Several Companies for Patent Infringement.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters